Prime Medicine Treats First Patient With In-Body Prime Editing in Wilson Disease Trial

3.8 · 9d ago · WORLD · TECH

The Facts

  • Prime Medicine, a biotechnology company in Cambridge, Massachusetts, announced it treated the first person in its clinical trial of prime editing for Wilson disease earlier this month. Nature only
  • Nature describes it as the first known instance of prime editing used to edit DNA directly inside a person's body (in vivo). Nature only
  • The treatment rewrites DNA in liver cells to erase a mutation that prevents them from eliminating excess copper. Nature only
  • Wilson disease is caused by mutations in the ATP7B gene, which encodes a protein that transports excess copper out of the liver; untreated, copper build-up can cause liver and nerve damage. Nature only
  • Prime Medicine expects to announce first results from the study next year. Nature only
Dive deeper · 4 more factsShow less
  • Base editing cannot make the corrections needed to fix the most common ATP7B mutations, which led to the use of prime editing. Nature only
  • In a separate trial, Prime Medicine used prime editing outside the body on blood stem cells of two people with a rare immune disorder, then reinjected the cells. Nature only
  • The FDA has approved only one gene-editing therapy, Casgevy (CRISPR-Cas9), for two inherited blood disorders; no in vivo gene-editing therapy is approved yet. Nature only
  • The FDA is expected to decide early next year on an in vivo CRISPR-Cas9 therapy for hereditary angioedema. Nature only

Context

Prime Medicine has begun dosing in a clinical trial of prime editing, a technique that can insert, delete and rewrite DNA segments with more precision than standard CRISPR-Cas9. The trial targets Wilson disease, a genetic disorder of copper handling currently managed with copper-clearing drugs and other medicines.

In vivo editing is seen as potentially cheaper and faster than editing a patient's extracted cells, though researchers note it carries its own risks. No results have been reported yet.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 2.

5 Science & Tech Analyst This is a notable first-in-human milestone for in vivo prime editing in a clinical trial, but it covers only dosing of a single patient with no results yet, affecting a small rare-disease population, so it is newsworthy but moderate in importance.
4 Global Affairs Analyst This is a notable first-in-human milestone for in vivo prime editing in a niche rare-disease trial with no results yet, so its impact is limited to a small patient population and the field, rating it moderately low.
4 Business Analyst This is a notable scientific first (in vivo prime editing dosing in a clinical trial) with long-term potential, but it is an early-stage trial milestone with no results yet and limited immediate economic or patient impact.
4 Policy Expert This is a company announcing the first patient dosed in an early-stage clinical trial, a scientifically notable milestone with no regulatory approval, no results yet, and limited immediate impact on patients beyond the trial.
4 Critical Reader This is a notable first-in-human dosing milestone for in vivo prime editing, but it is an early trial start with no results yet, affecting a small patient population, so its substantive impact is limited for now.
3 News Editor This is a concrete first-in-human clinical trial milestone affecting a single patient with a rare genetic disease, with no results yet, making it a niche medical advance of limited immediate impact.
3 Informed Citizen This is a notable scientific milestone (first in vivo prime editing dosing in a single patient in an early trial), but it has no immediate effect on ordinary people, no results yet, and a niche rare-disease scope, so it matters little within a week.

Source

← All stories